Conter et al., 2019 - Google Patents
Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and …Conter et al., 2019
View HTML- Document ID
- 7663694411014233020
- Author
- Conter H
- MacDonald L
- Fiset S
- Bramhecha Y
- Chaney M
- Rosu G
- Publication year
- Publication venue
- Annals of Oncology
External Links
Snippet
Background DPX-Survivac is a novel T cell activating therapy that has been shown to elicit a strong and prolonged immune response against tumors expressing survivin and correlated with clinical benefits in ovarian cancer. The survivin specific T cells activated by DPX …
- 206010028980 Neoplasm 0 title abstract description 18
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choueiri et al. | Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial | |
| Kang et al. | Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC)(PRODIGY) | |
| Halama et al. | Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer | |
| Fizazi et al. | Updated overall survival (OS) from the phase 3 trial, CA184-043: Ipilimumab (ipi) vs placebo (pbo) in patients with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) | |
| Conter et al. | Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts | |
| Even et al. | First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck | |
| Soria et al. | Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients (pts) in a phase I study of MPDL3280A | |
| Schmoll et al. | MODUL–a multicentre randomised clinical trial of biomarker-driven therapy for the 1st-line maintenance treatment of metastatic colorectal cancer (mCRC): a signal-seeking approach | |
| Fakih et al. | SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase | |
| Ji et al. | A phase Ib/II study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with mXELOX as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma | |
| Sadetsky et al. | Comprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting | |
| Bambury et al. | Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients | |
| Juncker-Jensen et al. | PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours | |
| Fuerea et al. | Early PSA response is an independent prognostic factor in patients with mCRPC treated with next-generation androgen pathway inhibitors | |
| Lassen et al. | Phase Ib trial trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in combination with cetuximab or erlotinib in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein | |
| Kim et al. | The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry | |
| Iganej et al. | 68P When is a Close or Positive Margin Following a Mastectomy an Indication for Chest Wall Radiotherapy in Patients with T1N0 Breast Cancer? | |
| Huszno et al. | The Association of Tumour Lymphocyte Infiltration with Clinicopathological Features in Breast Cancer Patients | |
| Kiyohara et al. | Long-term survival of patients with advanced melanoma in Phase 2 study of nivolumab (anti-PD-1; ONO-4538/BMS-936558) | |
| Hoyle | Key drivers of cost-effectiveness of anti-cancer drugs | |
| Husain et al. | Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment | |
| Chen | Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019 | |
| Sartore-Bianchi et al. | Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study | |
| Nerodo et al. | Status of Immune System As a Prognostic Factor in Vulvar Cancer Patients | |
| Qvortrup et al. | Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC) |